Author | Erika P. Hamilton, MD


How Can We Optimize Treatment of HER2-Positive Metastatic Breast Cancer?

March 15, 2013

Third, how much do we really know about de novo and acquired resistance to trastuzumab and lapatinib? There are several possible clinical relevant mechanisms of trastuzumab resistance, including crosstalk with other receptors, amplification of the PI3K/AKT pathway, alteration of the trastuzumab binding domain, and loss of HER2 expression.